Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Applied Genetic Technologies Corporation (AGTC)

5.12   -0.02 (-0.39%) 02-14 16:00
Open: 5.05 Pre. Close: 5.14
High: 5.25 Low: 5.05
Volume: 334,280 Market Cap: 94M
Applied Genetic Technologies Corp is a clinical-stage biotechnology company focused on gene therapy through a nontoxic adeno-associated virus. The company also offers products such as promoters, expression cassettes, and capsids for gene therapy.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 5.258 - 5.284 5.284 - 5.306
Low: 4.99 - 5.017 5.017 - 5.04
Close: 5.079 - 5.123 5.123 - 5.159

Technical analysis

as of: 2020-02-14 4:26:24 PM
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 9.68     One year: 12.17
Support: Support1: 4.84    Support2: 4.03
Resistance: Resistance1: 8.29    Resistance2: 10.42
Pivot: 6.05
Moving Average: MA(5): 5.07     MA(20): 6.64
MA(100): 4.25     MA(250): 4.03
MACD: MACD(12,26): -0.27     Signal(9): 0.05
Stochastic oscillator: %K(14,3): 6.19     %D(3): 4.17
RSI: RSI(14): 42.91
52-week: High: 10.42  Low: 2.52  Change(%): 53.3
Average Vol(K): 3-Month: 131230  10-Days: 83956

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
AGTC has closed above bottom band by 25.8%. Bollinger Bands are 71.9% wider than normal. The large width of the bands suggest high volatility as compared to AGTC's normal range. The bands have been in this wide range for 36 bars. This is a sign that the current trend might continue.

Headline News

The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 5.) Alector Inc (NASDAQ: ALEC ) (announced granting of Fast Track Designation to its AL101 for the treatment of patients with frontotemporal dementia) Arvinas Inc (NASDAQ: ARVN ) Ascendis Pharma A/S (NASDAQ: ASND ) Biogen Inc (NASDAQ: BIIB ) (won patent challenge on multiple sclerosis drug Tecfidera) BioXcel Therapeutics Inc (NASDAQ: BTAI ) (announced FDA clearance of IND for BXCL501 to treat opioid withdrawal symptoms) ChemoCentryx Inc (NASDAQ: CCXI ) Eli Lilly And Co (NYSE: LLY ) Insmed Incorporated (NASDAQ: INSM ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Insulet Corporation (NASDAQ: PODD ) Johnson & Johnson (NYSE: JNJ ) Masimo Corporation (NASDAQ: MASI ) Medpace Holdings Inc (NASDAQ: MEDP ) Molecular Templates Inc (NASDAQ: MTEM ) Novo Nordisk A/S (NYSE: NVO ) (reacted to quarterly results ) Profound Medical Corp (NASDAQ: PROF ) (announced retirement of bank debt ahead of schedule) PTC Therapeutics, Inc (NASDAQ: PTCT ) Quest Diagnostics Inc (NYSE: DGX ) Reata Pharmaceuticals Inc (NASDAQ: RETA ) Repligen Corporation (NASDAQ: RGEN ) ResMed Inc. (NYSE: RMD ) Revance Therapeutics Inc (NASDAQ: RVNC ) Theravance Biopharma Inc (NASDAQ: TBPH ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Down In The Dumps (Biotech stocks that hit 52-week lows Feb. 5.) Endologix, Inc. (NASDAQ: ELGX ) Salarius Pharmaceuticals Inc (NASDAQ: SLRX ) Spring Bank Pharmaceuticals Inc (NASDAQ: SBPH ) See also: The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus Stocks In Focus Sanofi's Multiple Sclerosis Drug Aces Midstage Trial; Q4 Sales, Net Income Rise Sanofi SA (NASDAQ: SNY ) said a Phase 2b study that evaluated its investigational BTK inhibitor SAR442168 for multiple sclerosis met the primary endpoint, …

Ag Shippers Want More Container "Free Time" During Coronavirus Outbreak
A group of American agriculture and forest products shippers wants the ocean carriers in the U.S.-China trade to extend the "free-time" deadlines for containers delayed in marine terminals due to the impact of the coronavirus on international shipping. "While this is open-ended, our U.S. exporters need assurance they will not be charged detention (per diem) or demurrage while the supply chain remains dysfunctional due to the Coronavirus," wrote Peter Friedmann, executive director of the Washington-based Agriculture Transportation Coalition (AgTC) in a letter to the ocean container carriers on Monday. Demurrage pertains to the time an import container sits in a container terminal, with carriers responsible for collecting penalties on behalf of the marine terminals. Detention, also known as per diem, relates to shippers holding containers for too long outside the marine terminals. Typically, shippers face $150 to $350 demurrage and detention fees assessed daily by the ocean … Full story available on Benzinga.

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ Global Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 18.22
Shares Float (M) 11.37
% Held by Insiders 17.57
% Held by Institutions 61.62
Shares Short (K) 72
Shares Short P. Month (K)

Stock Financials

EPS -0.820
Book Value (p.s.) 3.730
PEG Ratio
Profit Margin -53.45
Operating Margin -61.81
Return on Assets (ttm) -10.6
Return on Equity (ttm) -20.1
Qtrly Rev. Growth
Gross Profit (p.s.) 1.529
Sales Per Share
EBITDA (p.s.) -0.868
Qtrly Earnings Growth
Operating Cash Flow (M) -34.76
Levered Free Cash Flow (M) -22.19

Stock Valuations

P/E -6.24
P/E Growth Ratio
P/BV 1.37
P/S 3.36
P/CF -2.68

Dividends & Splits

Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date
Last Split Ratio -1e+010
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2019 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.